Marquardt, V., Theruvath, J., Pauck, D., Picard, D., Qin, N., Blümel, L., . . . Mitra, S. (2023). Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. Journal for ImmunoTherapy of Cancer, 11(1), . https://doi.org/10.1136/jitc-2022-005871
Chicago-Zitierstil (17. Ausg.)Marquardt, Viktoria, et al. "Tacedinaline (CI-994), a Class I HDAC Inhibitor, Targets Intrinsic Tumor Growth and Leptomeningeal Dissemination in MYC-driven Medulloblastoma While Making Them Susceptible to Anti-CD47-induced Macrophage Phagocytosis via NF-kB-TGM2 Driven Tumor Inflammation." Journal for ImmunoTherapy of Cancer 11, no. 1 (2023). https://doi.org/10.1136/jitc-2022-005871.
MLA-Zitierstil (9. Ausg.)Marquardt, Viktoria, et al. "Tacedinaline (CI-994), a Class I HDAC Inhibitor, Targets Intrinsic Tumor Growth and Leptomeningeal Dissemination in MYC-driven Medulloblastoma While Making Them Susceptible to Anti-CD47-induced Macrophage Phagocytosis via NF-kB-TGM2 Driven Tumor Inflammation." Journal for ImmunoTherapy of Cancer, vol. 11, no. 1, 2023, https://doi.org/10.1136/jitc-2022-005871.